NCT01484600已完成1 期
Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of REGN668 Administered Subcutaneously to Healthy Volunteers
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 36
- 试验地点
- 1
- 主要终点
- Incidence and severity of treatment-emergent adverse events (TEAEs)
研究概览
简要总结
This is a study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of REGN668 Administered Subcutaneously to Healthy Volunteers.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Male or female subjects 18 to 55 years of age.
- •Body weight between 60 kg and 80 kg, body mass index between 20 and 30 kg/m2 inclusive.
- •NHV as evidenced by comprehensive clinical assessment (detailed medical history and complete physical examination).
- •Normal resting blood pressure and heart rate
- •Willingness to refrain from the consumption of alcohol for 24 hours prior to each study visit.
排除标准
- •History or presence of currently relevant medical conditions, including any cardiovascular, pulmonary, gastrointestinal, hepatic, renal, metabolic, hematological, neurological, musculoskeletal, psychiatric, systemic, ocular, infectious or parasitic disease, or signs of acute illness.
- •Administration of any medications within 1 week before randomization, other than vitamins, nutritional supplements, or low doses of aspirin taken prophylactically.
- •Onset of a new exercise routine or major change to a previous exercise routine within 2 weeks prior to randomization. Subjects must be willing to maintain a relatively constant level of exercise during the study and refrain from unusually strenuous physical activities
- •Known history of human immunodeficiency virus (HIV) antibody; and/or positive hepatitis B surface antigen (HBsAg), and/or positive hepatitis C antibody (HCV) at the screening visit.
- •History of substance (eg. drug or alcohol) abuse or regular (daily) smoking within a year prior to randomization or positive results on urine drug screen.
- •Excessive consumption of beverages with xanthine derivates (caffeine, theophylline, theobromine), such as coffee, tea, cola, or yerba mate (more than 4 cups or glasses per day).
- •Hospitalization for any reason within 60 days of randomization.
- •Participation in any clinical research study evaluating another investigational drug or therapy within 30 days of the investigational drug, whichever is longer, prior to the randomization visit.
- •Live/attenuated vaccinations within 12 weeks of randomization or during the study.
- •Tuberculosis vaccination within the last year.
- •Previous exposure to any other biological agent within 12 months of randomization.
- •History of a hypersensitivity reaction to doxycycline or other tetracyclines.
- •Recent travel (within 12 months of randomization) to areas endemic for parasitic helminthes, such as developing countries, particularly in Africa and the tropical and subtropical regions of Asia.
- •Pregnant or breast-feeding women.
- •Unwilling to use adequate birth control if of reproductive potential and sexually active
结局指标
主要结局
Incidence and severity of treatment-emergent adverse events (TEAEs)
时间窗: Baseline through day 64 (end of study)
次要结局
- Pharmacokinetic (PK) profile of REGN668(Baseline through day 64)
- Incidence of anti-REGN668 antibodies(Day 29 and Day 64)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Sequential Ascending Dose Study to Assess the Safety and Tolerability of REGN668 (SAR231893) in Patients With Atopic DermatitisDermatitisNCT01259323Regeneron Pharmaceuticals30
已完成
1 期
Ascending Dose Study of the Safety and Tolerability of REGN668(SAR231893) in Normal Healthy VolunteersHealthyNCT01015027Regeneron Pharmaceuticals48
尚未招募
1 期
Study of the Drug B11-FC (Botulism Treatment)BotulismNCT06580236Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation40
招募中
1 期
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other TumorsClear Cell Renal Cell Carcinoma (ccRCC)NCT03972657Regeneron Pharmaceuticals345
招募中
1 期
Study of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid TumorsAdvanced Solid TumorNCT04855656Debiopharm International SA464